title: Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection.
abstract: Nonmenstrual toxic shock syndrome (TSS) due to Staphylococcus aureus can lead to significant morbidity and mortality. While drotrecogin alfa (DA) has been employed in patients with Methicillin-resistant Staphylococcus aureus (MRSA) severe sepsis and septic shock, its utility in TSS remains unclear. The authors report a case of severe sepsis in the setting of MRSA-associated TSS that responded to treatment with DA. This case illustrates a potential role for DA in the treatment of toxic shock syndromes and emphasizes the importance of aggressive diagnostic and therapeutic modalities in approaching these conditions.
authors.affiliation: Department of Internal Medicine, Division of Infectious Diseases, East Tennessee State University, Box 70622, Johnson City, TN 37614, USA. alhaddad@mail.etsu.edu
authors.forename: Dafer W
authors.initials: DW
authors.lastname: Haddadin
authors.forename: Imran Q
authors.initials: IQ
authors.lastname: Samnani
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Moorman
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000382:microbiology; D005260:Female; D059685:Herniorrhaphy; D006801:Humans; D016106:Methicillin Resistance; D008875:Middle Aged; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012121:Respiration, Artificial; D012772:Shock, Septic / Q000188:drug therapy* / Q000382:microbiology* / Q000628:therapy; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013526:Surgical Mesh; D013530:Surgical Wound Infection / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated